It's certainly not looking that way. I'm a little surprised that management hasn't seized the opportunity to announce the final data officially given the additional PR/CR recorded.
What I did find, though, was another co. that presented at the WCCL meeting. Initially, I was startled by the existence of a rival in the field of CTCL. However, Resminostat is described as a "maintenance" therapy and whilst the data seems impressive, the Progression Free duration for those in the placebo group seems exceptionally long.
https://www.4sc.com/product-pipeline/resminostat/
In visiting their website, it appears (if I have interpreted it correctly) that the trial involves patients with less advanced CTCL than what PTX-100 has been treating. PTX-100 has only been tested on patients who have failed between 3 and 6 prior lines of treatment.
https://www.4sc.com/news/4sc-ag-resmain-trial-meets-primary-endpoint-in-cutaneous-t-cell-lymphoma-ctcl/
Not sure what this means: "Given that the RESMAIN study did not meet its key secondary objective, 4SC will now approach the European Medicines Agency in order to better understand the feasibility of submitting a Marketing Authorization Application."
It's certainly not looking that way. I'm a little surprised that...
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $37.04M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.6¢ | $94.55K | 2.033M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 550000 | 2 |
View Market Depth
| Last trade - 15.36pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.8¢ |
Change
-0.002 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 4.7¢ | 4.8¢ | 4.5¢ | 409565 | ||
| Last updated 15.51pm 03/05/2024 ? | |||||
| PTX (ASX) Chart |